
|Articles|November 19, 2020
- November digital edition 2020
- Volume 12
- Issue 11
Quiz Answers: Treatments for presbyopia coming soon
Author(s)Brooke Henson, Editor
Advertisement
1. What is the prevalence of presbyopia in the U.S.?
a. 5,000,000
b. 10,500,000
c. 50,000,000
d. 110,000,000
2. Miotics have few side effects.
a. True
b. False
3. Which of these devices uses pinhole optics (PHO)?
a. Revision Raindrop
b. Karama Inlay
c. FOV Tears
d. Allergan Presbysol
e. B and D
4. Which of these is not a pharmaco-refractive product?
a. Oraisis CSF-1
b. Presbyopia Therapies PRX-100
c. Allergan AGN
d. Eyenovia Micro-dose
e. All are pharmaco-refractive
5. What is the most common ingredient in current pharmaceutical drops for presbyopia being tested?
a. Dexamethasone
b. Pilocarpine
c. Bromfenac
d. Tropicamide
e. None of the above
6. Which of these is a device?
a. Oraisis CSF-1
b. Presbyopia Therapies PRX-100
c. Allergan AGN
d. Eyenovia Micro-dose
e. FOV Tears
7. Which is an active ingredient in PRX-100?
a. Pilocarpine
b. Tropicamide
c. Oxymetazoline
d. Polyethylene glycol
e. Diclofenac
Articles in this issue
over 5 years ago
Quiz: Treatments for presbyopia coming soonover 5 years ago
When to lease and when to own office spaceover 5 years ago
Vision rehabilitation of patients with strokeover 5 years ago
Treatments for presbyopia coming soonover 5 years ago
How diabetes affects COVID-19over 5 years ago
Novel uses of technology for systemic diseaseover 5 years ago
Know the pros and cons of outsourcing billingover 5 years ago
5 communication strategies for dry eye patientsAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Bausch + Lomb launches preservative-free version of Blink Triple Care eye drops
2
Exercise for the prevention and mitigation of eye disease
3
Georgia university receives state funding for state's first college of optometry
4
Recent study findings may prove previous estimations of retinal cell communication, low-light vision
5





















